cancertechnology.co.uk Report : Visit Site

Technical data of the cancertechnology.co.uk

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host cancertechnology.co.uk. Currently, hosted in Ireland and its service provider is Amazon.com Inc. .

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

-- -- cancer research technology search form search commercial partnerships home about overview our people our network history services overview project development have an idea? commercialisation drug discovery cruk drug discovery clinical development cdp imaging funding projects overview our pipeline licensing opportunities small molecules biological therapeutics enabling technology medical devices biomarkers our start-ups research tools research tools news and events news and events alliance of translational research centres established to accelerate global drug development astex pharmaceuticals earns $5.4 m milestone on phi trial initiation of a fgfr kinase inhibitor crt & adc therapeutics join forces on antibody drug conjugates crt and teva pharmaceuticals form r&d alliance for cancer dna damage response drugs crt, the institute of cancer research and merck serono sign wnt licensing deal cruk cambridge institute symposium cancer research uk and crt collaborate with abcodia to discover and develop tests for cancer forma therapeutics and crt to discover cancer drugs targeting deubiquitinating enzymes (dubs) new board appointment for crt new offices for crt "this is a great place to come and do business" 2014 bio international convention 2014 medicinal chemistry gordon research conference 2014 year in review infographic 2015 bio international convention 2016 bio international convention 26th eortc-nci-aacr symposium 28th eortc-nci-aacr symposium aacr annual meeting aacr annual meeting 2015 aacr annual meeting 2016 aacr annual meeting 2017 aacr-nci-eortc 2015 autm 2015 annual meeting autm 2016 annual meeting academic drug discovery workshop accelerator structural biology conference 2016 achilles therapeutics launched with funds of £13.2 million to develop immunotherapies for cancer alchemia announces in-licensing of fak inhibitors from crt bacit seeks shareholder approval to commit £20m and join crt pioneer fund as a limited partner bicycle therapeutics and cancer research uk named best partnership alliance of the year at 2017 scrip awards bio-europe spring 2016 bio-europe spring 2014 bio-europe 2015 bio-europe autumn 2016 bio-europe spring 2017 bio-homecoming 2016 bioinvents bi-1206 antibody to enter collaborative phase i/ii trial biowednesday: future directions in oncology biotech and money london 2015 biotechs and the city cancer research technology and varleigh dx (uk) ltd launch test to support diagnosis of pancreatic cancer crt highlighted in the dowling review of business-university research collaborations crt pioneer fund banks £20m investment from bacit and expands agreement with chroma therapeutics crt pioneer fund collaborates with chroma therapeutics crt pioneer fund, bacit and sareum enter agreement crt pioneer fund, cancer research uk and nci collaborate to boost research against the ‘undruggable’ ras crt and alta innovations join forces to commercialise world-leading research crt and astrazeneca expand successful multi-project cancer metabolism alliance crt and bioinvent expand collaboration with university of southampton scientists crt and sv life sciences form artios pharma to focus on dna damage response crt and teva’s collaboration yields successful outcome with novel apkc protein inhibitor cancer drug discovery candidate crt and the icr enter collaboration with janssen to discover multiple myeloma drug crt and university of copenhagen announce agreement with adc therapeutics to develop antibody treatments for cancer crt and university of manchester receive success payment from glaxosmithkline for cancer epigenetics research collaboration crt announces license agreement with msd to develop inhibitors of prmt5 for cancer and blood disorders crt drives novel and collaborative drug discovery in areas of "hot" cancer science crt signs agreement with cimass for the development of a monoclonal antibody in the treatment of cancer. crt unveils screen test for potential drugs to treat oestrogen positive breast cancer crt, university of manchester and glaxosmithkline work together to generate new cancer drugs crt’s discovery laboratories extends alliance with merck to develop new cancer drugs cruk, crt and asterias biotherapeutics partner to trial immunotherapy vaccine for lung cancer call for small molecules as tool compounds cancer advance harvard med cancer drug discovery and preclinical development summit cancer research technology pioneer fund announces investment in blood cancer drugs cancer research technology and forma therapeutics: an excellent marriage cancer research technology and medivir collaborate to develop new class of cancer drugs cancer research technology and nuevolution sign multi-target deal to seek potential cancer drugs cancer research technology and pangaea biotech sign license agreement for new cancer drugs cancer research technology appoints deborah harland as non-executive director cancer research technology introduces ximbio, an online reagents portal cancer research technology, ucl, and tusk therapeutics join forces to develop cancer immunotherapies cancer research uk and bicycle therapeutics have collaborated to trial new therapy for advanced solid tumours cancer research uk and astrazeneca sign deal to repurpose asthma drug that could fight kidney cancer cancer research uk and cancer research technology announce partnership with monopar therapeutics cancer research uk and cancer research technology join forces with astellas on autophagy to find new cancer treatments cancer research uk and cancer research technology partner with tyg oncology to develop next generation cancer vaccine cancer research uk and leukaemia & lymphoma research team up to boost blood cancer trials cancer research uk and medimmune establish joint cruk-medi alliance laboratory to develop new biologic cancer medicines cancer research uk and medimmune launch ground-breaking biotherapeutics research centre in cambridge cancer research uk and newcastle university extend successful multi-project drug discovery alliance with astex pharmaceuticals cancer research uk and the institute of cancer research, london, join forces with merck in new drug discovery alliance cancer research uk announces drug discovery collaboration with celgene corporation cancer research uk brings commercialisation arm in-house cancer research uk drug launched in its first clinical trial cancer research uk to collaborate with astrazeneca in screening for new cancer medicines cancer research uk, crt and amgen to trial leukaemia immunotherapy drug in other cancers consortium signs deal with basilea to develop resistance-busting cancer drugs elrig drug discovery 2015 faseb: lipids and lipid regulated kinases in cancer forma therapeutics and crt form a third virtual company to advance deubiquitination assets forma therapeutics and crt form two virtual companies to advance deubiquitination assets gammadelta therapeutics raises seed funding from abingworth glythera licenses novel payload class from cancer research uk for the development of next-generation antibody drug conjugates highlights from the ncri conference 2013 hitgen announces collaboration in drug discovery hitgen and cancer research uk’s manchester institute enter licence agreement in lung cancer how we are advancing discoveries to beat cancer inivata completes £31.5 million ($45m) series a fundraising round inivata raises £4m to realise the potential of ctdna analysis to improve cancer treatment through simple blood tests instinctif partners hosts cancer research technology event on innovative cancer diagnostics and treatments international deal to screen potential cancer drugs using dna 'barcodes' major drug discovery feasibility study with merck serono mission therapeutics raises £60 million to progress development of novel dub inhibitors from innovative drug platform mrc technology, cancer research uk and cancer research technology collaborate to focus on cancer immunotherapies merck ventures crea

URL analysis for cancertechnology.co.uk

http://commercial.cancerresearchuk.org/node?qt-front_page_tabs=2#qt-front_page_tabs
http://commercial.cancerresearchuk.org/cancer-research-technology-and-pangaea-biotech-sign-license-agreement-new-cancer-drugs
http://commercial.cancerresearchuk.org/crt-and-sv-life-sciences-form-artios-pharma-focus-dna-damage-response
http://commercial.cancerresearchuk.org/inivata-completes-%c2%a3315-million-45m-series-fundraising-round
http://commercial.cancerresearchuk.org/two-cancer-research-technology-deals-shortlisted-leading-industry-awards
http://commercial.cancerresearchuk.org/valneva-and-blink-therapeutics-confirm-launch-and-funding-blink-biomedical
http://commercial.cancerresearchuk.org/lo-enabling-technology-search
http://commercial.cancerresearchuk.org/alchemia-announces-licensing-fak-inhibitors-crt
http://commercial.cancerresearchuk.org/licensing-opportunites
http://commercial.cancerresearchuk.org/2014-bio-international-convention
http://commercial.cancerresearchuk.org/structuralbiology2016
http://commercial.cancerresearchuk.org/inivata-raises-%c2%a34m-realise-potential-ctdna-analysis-improve-cancer-treatment-through-simple-blood
http://commercial.cancerresearchuk.org/cancer-research-uk-and-cancer-research-technology-announce-partnership-monopar-therapeutics-develop
http://commercial.cancerresearchuk.org/aacr2016
http://commercial.cancerresearchuk.org/our-people
cancertechnology.co.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Error for "cancertechnology.co.uk".

the WHOIS query quota for 2600:3c03:0000:0000:f03c:91ff:feae:779d has been exceeded
and will be replenished in 147 seconds

WHOIS lookup made at 13:18:26 14-Jul-2018

--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:

Copyright Nominet UK 1996 - 2018.

You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at https://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REFERRER http://www.nominet.org.uk

  REGISTRAR Nominet UK

SERVERS

  SERVER co.uk.whois-servers.net

  ARGS cancertechnology.co.uk

  PORT 43

  TYPE domain

DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2018.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at https://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REGISTERED no

DOMAIN

  NAME cancertechnology.co.uk

NSERVER

  NS1.NAMECITY.COM 62.128.193.35

  NS2.NAMECITY.COM 84.22.161.171

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .